2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
555
Lymphoma
447
Precursor Cell Lymphoblastic Leukemia-Lymphoma
413
Lymphoma, Large B-Cell, Diffuse
348
Leukemia
346
Multiple Myeloma
336
Lymphoma, Non-Hodgkin
317
Leukemia, Myeloid, Acute
289
Leukemia, Lymphocytic, Chronic, B-Cell
286
Lymphoma, Follicular
241
Burkitt Lymphoma
217
Myelodysplastic Syndromes
211
Lymphoma, Mantle-Cell
202
Hodgkin Disease
193
Recurrence
155
Lymphoma, B-Cell, Marginal Zone
142
Melanoma
136
Lymphoma, Large-Cell, Immunoblastic
116
Neoplasms
109
Lymphoma, B-Cell
103
Neuroblastoma
101
Neoplasms, Plasma Cell
99
Ovarian Neoplasms
96
Triple Negative Breast Neoplasms
94
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
91
Myeloproliferative Disorders
87
Hematologic Neoplasms
87
Leukemia, Myeloid, Chronic-Phase
83
Leukemia, Myeloid, Accelerated Phase
80
Leukemia, Myelomonocytic, Chronic
78
Interventions
olaparib
1
niraparib
1
fluzoparib
1
Vernalization
1
Standard of Care
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Irinotecan
1
Epirubicin
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kenny-Caffey syndrome, Type 1
×
Cyclophosphamide
×
Clear all
NCT02789332
2020-03-17
GeparOla
GBG Forschungs GmbH
Phase 2
Completed
107 enrolled